RGC

Regencell BioscienceC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$35.17

+51.9% vs current

Most likely

Base case

60%

Probability

Target price

$31.13

+34.5% vs current

B-

Bear case

20%

Probability

Target price

$26.67

+15.2% vs current

AI sentiment snapshot

Latest data as of 2026-01-16

AI commentary

Market sentiment is mixed-to-cautious: public snippets show a very wide 52-week range and divergent short-term quotes, indicating episodic trading and elevated volatility [#SERP-1][#SERP-4]. Sparse analyst footprints cluster around a low/median/high band used above, suggesting modest consensus upside from the 29 anchor but heavy dependence on binary events for re-rating [#SERP-10]. Given limited coverage and funding dependence, our 'buy' rating is conditional and hinges on short-term catalysts that could move the stock toward the base/bull targets.

RankAlpha Sentiment AI - 2026-01-16

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-16catalystNear-term corporate update / liquidity signalHigh impact

Possible market reaction to a quarterly corporate update or liquidity/operational disclosure; recent public data shows wide intrayear price swings and thin coverage, suggesting outsized moves on any material update [#SERP-1][#SERP-4].

2027-01-16catalystProgram milestone / re-rating opportunityHigh impact

Longer-term value realization tied to clinical/commercial progress or strategic transaction potential; consensus coverage is limited and third‑party forecasters show divergent long-run views [#SERP-10][#SERP-5].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-16 • Updated nightlySource: Internal modelMethodology